REFERENCES
- Mansour D, Inki P, Gemzell-Danielsson K. Efficacy of contraceptive methods: A review of the literature. Eur J Contracept Reprod Health Care 2010;15:4–16.
- National Institute for Health and Clinical Excellence. Long-acting reversible contraception. Clinical Guideline 30. London: RCOG Press 2005. Accessed 18 July 2011 from: http://www.nice.org.uk/CG030.
- Trussell J, Lalla AM, Doan QV, . Cost-effectiveness of contraceptives in the United States. Contraception 2009;79:5–14.
- Blumenthal PD, Voedisch A, Gemzell-Danielsson K. Strategies to prevent unintended pregnancy: Increasing use of long-acting reversible contraception. Hum Reprod Update 2011;17:121–37.
- ACOG Committee Opinion no 450: Increasing use of contraceptive implants and intrauterine devices to reduce unintended pregnancy. Obstet Gynecol 2009;114:1434–8.
- Heimovitch S. Profile of long-acting contraceptive method users in Europe. Eur J Contracept Reprod Health Care 2009;14:187–95.
- Peipert JF, Zhao Q, Allsworth JE, . Continuation and satisfaction of reversible contraception. Obstet Gynecol 2011;117:1105–13.
- Harvey C, Seib C, Lucke J. Continuation rates and reasons for removal among Implanon users accessing two family planning clinics in Queensland, Australia. Contraception 2009;80:527–32.
- Arribas-Mir L, Rueda-Lozano D, Agrela-Cardona M, . Insertion and 3-year follow-up experience of 372 etonogestrel subdermal contraceptive implants by family physicians in Granada, Spain. Contraception 2009; 80:457–462.
- Mansour D, Bahamondes L, Critchley H, . The management of unacceptable bleeding patterns in etonogestrel-releasing contraceptive implant users. Contraception 2011;83:202–10.
- Backman T, Huhtala S, Blom T, . Length of use and symptoms associated with premature removal of the levonorgestrel intrauterine system: A nation-wide study of 17,360 users. BJOG 2000;107: 335–9.
- Lakha F, Glasier AF. Continuation rates of Implanon in the UK: Data from an observational study in a clinical setting. Contraception 2006;74:287–89.